title: Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.
abstract: Current influenza virus vaccines contain H1N1 (phylogenetic group 1 hemagglutinin), H3N2 (phylogenetic group 2 hemagglutinin), and influenza B virus components. These vaccines induce good protection against closely matched strains by predominantly eliciting antibodies against the membrane distal globular head domain of their respective viral hemagglutinins. This domain, however, undergoes rapid antigenic drift, allowing the virus to escape neutralizing antibody responses. The membrane proximal stalk domain of the hemagglutinin is much more conserved compared to the head domain. In recent years, a growing collection of antibodies that neutralize a broad range of influenza virus strains and subtypes by binding to this domain has been isolated. Here, we demonstrate that a vaccination strategy based on the stalk domain of the H3 hemagglutinin (group 2) induces in mice broadly neutralizing anti-stalk antibodies that are highly cross-reactive to heterologous H3, H10, H14, H15, and H7 (derived from the novel Chinese H7N9 virus) hemagglutinins. Furthermore, we demonstrate that these antibodies confer broad protection against influenza viruses expressing various group 2 hemagglutinins, including an H7 subtype. Through passive transfer experiments, we show that the protection is mediated mainly by neutralizing antibodies against the stalk domain. Our data suggest that, in mice, a vaccine strategy based on the hemagglutinin stalk domain can protect against viruses expressing divergent group 2 hemagglutinins.
authors.affiliation: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
authors.forename: I
authors.initials: I
authors.lastname: Margine
authors.forename: F
authors.initials: F
authors.lastname: Krammer
authors.forename: R
authors.initials: R
authors.lastname: Hai
authors.forename: N S
authors.initials: NS
authors.lastname: Heaton
authors.forename: G S
authors.initials: GS
authors.lastname: Tan
authors.forename: S A
authors.initials: SA
authors.lastname: Andrews
authors.forename: J A
authors.initials: JA
authors.lastname: Runstadler
authors.forename: P C
authors.initials: PC
authors.lastname: Wilson
authors.forename: R A
authors.initials: RA
authors.lastname: Albrecht
authors.forename: A
authors.initials: A
authors.lastname: García-Sastre
authors.forename: P
authors.initials: P
authors.lastname: Palese
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D000918:Antibody Specificity; D002478:Cells, Cultured; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005455:Fluorescent Antibody Technique; D005822:Genetic Vectors / Q000008:administration & dosage*; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics / Q000276:immunology*; D006801:Humans; D009980:Influenza A virus / Q000145:classification / Q000502:physiology*; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007668:Kidney / Q000276:immunology / Q000378:metabolism / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D010802:Phylogeny
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines
references.citation: J Virol. 2011 Jul;85(14):6832-43
references.pmid: 21543486
references.citation: J Virol. 2012 Jun;86(11):6179-88
references.pmid: 22491456
references.citation: MMWR Morb Mortal Wkly Rep. 2013 Feb 22;62(7):119-23
references.pmid: 23425960
references.citation: Vaccine. 2003 May 1;21(16):1776-9
references.pmid: 12686093
references.citation: Nat Struct Mol Biol. 2009 Mar;16(3):265-73
references.pmid: 19234466
references.citation: PLoS One. 2011;6(10):e26818
references.pmid: 22046370
references.citation: Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9047-52
references.pmid: 22615367
references.citation: Clin Infect Dis. 2011 Apr 15;52(8):1003-9
references.pmid: 21460314
references.citation: Science. 2011 Aug 12;333(6044):850-6
references.pmid: 21798894
references.citation: J Virol. 2007 Oct;81(19):10558-66
references.pmid: 17634234
references.citation: PLoS One. 2011;6(10):e25797
references.pmid: 22039424
references.citation: J Virol. 2013 Apr;87(8):4728-37
references.pmid: 23408625
references.citation: Lancet. 1975 Oct 18;2(7938):729-32
references.pmid: 52768
references.citation: Emerg Infect Dis. 2012 May;18(5):814-6
references.pmid: 22516302
references.citation: MMWR Morb Mortal Wkly Rep. 2012 Jul 27;61(29):561
references.pmid: 22832938
references.citation: Clin Infect Dis. 2013 May;56(10):1363-9
references.pmid: 23413420
references.citation: N Engl J Med. 2013 May 16;368(20):1888-97
references.pmid: 23577628
references.citation: J Virol. 2013 Jun;87(12):6901-10
references.pmid: 23576512
references.citation: Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17040-5
references.pmid: 23027945
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1356-61
references.pmid: 14745020
references.citation: Nature. 2008 May 29;453(7195):667-71
references.pmid: 18449194
references.citation: J Infect Dis. 2013 Jan 1;207(1):98-105
references.pmid: 23087428
references.citation: Science. 2012 Sep 14;337(6100):1343-8
references.pmid: 22878502
references.citation: Nature. 2012 Sep 27;489(7417):526-32
references.pmid: 22982990
references.citation: Science. 2009 Apr 10;324(5924):246-51
references.pmid: 19251591
references.citation: J Virol. 2012 Oct;86(19):10302-7
references.pmid: 22787225
references.citation: J Exp Med. 2011 Jan 17;208(1):181-93
references.pmid: 21220454
references.citation: Emerg Infect Dis. 2004 Dec;10(12):2196-9
references.pmid: 15663860
references.citation: J Infect Dis. 2001 Sep 15;184(6):665-70
references.pmid: 11517426
references.citation: Infect Genet Evol. 2013 Jul;17:162-87
references.pmid: 23541413
references.citation: Front Immunol. 2012 May 08;3:87
references.pmid: 22586427
references.citation: Euro Surveill. 2013 Apr 25;18(17):20465
references.pmid: 23647627
references.citation: Nature. 1979 May 17;279(5710):246-8
references.pmid: 86955
references.citation: J Virol. 2013 Jun;87(12):6542-50
references.pmid: 23576508
references.citation: JAMA. 2000 Oct 4;284(13):1655-63
references.pmid: 11015795
references.citation: Science. 2011 Aug 12;333(6044):843-50
references.pmid: 21737702
references.citation: MMWR Morb Mortal Wkly Rep. 2012 Sep 14;61(36):726-7
references.pmid: 22971746
references.citation: mBio. 2010 May 18;1(1):
references.pmid: 20689752
references.citation: J Virol. 2012 Jun;86(11):6334-40
references.pmid: 22457520
references.citation: PLoS Pathog. 2010 Feb 26;6(2):e1000796
references.pmid: 20195520
references.citation: Nature. 2007 Apr 12;446(7137):801-5
references.pmid: 17325668
references.citation: PLoS One. 2012;7(8):e43603
references.pmid: 22928001
references.citation: mBio. 2012 Jul 31;3(4):e00166-12
references.pmid: 22851656
references.citation: J Clin Invest. 2010 May;120(5):1663-73
references.pmid: 20389023
references.citation: Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2573-8
references.pmid: 22308500
references.citation: J Virol. 2012 May;86(10):5774-81
references.pmid: 22398287
references.citation: Vaccine. 1999 Jul 30;17 Suppl 1:S42-6
references.pmid: 10471179